Genolution

Genolution Debt/EBITDA

The Total Debt to EBITDA Ratio of Genolution (225220.KQ) as of Nov 11, 2026 is -3.00. In the previous year, Total Debt to EBITDA Ratio was -3.40 — a change of -11.84% (higher).

Debt/EBITDA

-3.00

YoY

-11.84%

Last updated:

Total Debt to EBITDA Ratio of Genolution is 2024 -3.00 . Total Debt to EBITDA Ratio of Genolution was 2023 -3.40 . It decreases by -11.84% higher compared to the previous year.

The Genolution Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.00 KRW
Jan 1, 2018
4.07 KRW
Jan 1, 2019
8.77 KRW
Jan 1, 2020
0.12 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.95 KRW
Jan 1, 2023
-3.40 KRW
Jan 1, 2024
-3.00 KRW
The Genolution Debt/EBITDA history
YEARDebt/EBITDAYoY
-3.00-11.84%
-3.40-459.18%
0.95—
0.00-100.00%
0.12-98.61%
8.77+115.45%
4.07—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Total Debt to EBITDA Ratio of Genolution is -3.00 in 2024.

Total Debt to EBITDA Ratio of Genolution changed from -3.40 to -3.00, representing a -11.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genolution

All Key Metrics — Genolution